Hypoxia in the tumor microenvironment may cause resistance to irinotecan not only for tumor cells but for CD8+ T cells in tumors by promoting the anti-apoptotic and pro-survival mechanisms of CD8+ T cells. Here, CD8A is linked to neoplasm.